Radiopharm (ASX:RAD) secures key isotope from ANSTO for lung cancer trial

November 23, 2022 11:09 AM AEDT | By Aditi Sarkar

Radiopharm (ASX:RAD) secures key isotope from ANSTO for lung cancer trial — Image source: © Terovesalainen | Megapixl.com

Lu-177 - Key isotope for Radiopharm’s Phase I therapeutic trial

Radiopharm needs Lu-177, an isotope non-carrier-added lutetium-177, for its trials in Australia.

The isotope is planned to be used in combination with Radiopharm's propriety nanobody in a Phase I therapeutic dose-escalation trial. The clinical trial would focus on patients with non-small cell lung cancer.

Radiopharm plans to commence the trial in Q1 2023 in partnership with GenesisCare and ANSTO.

The agreement will come into effect from 01 December 2022.

Shaun Jenkinson, CEO of ANSTO, said “We are excited that the isotopes we will supply to Radiopharm Theranostics will go toward expanding this vision at it seeks to revolutionise cancer treatment.”

This is what Radiopharm CEO and Managing Director has to say

Inside Radiopharm’s key agreements during 2022

This year, Radiopharm has secured several key agreements for the smooth running of its clinical trials.

RAD shares were trading at AU$0.120 apiece in the early hours of 23 November 2022.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.